98 related articles for article (PubMed ID: 5637944)
41. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
42. Elevated glucose in pleural effusion: an early clue to esophageal perforation.
Almoosa KF; Wardell N; Javaheri S
Chest; 2007 May; 131(5):1567-9. PubMed ID: 17494806
[TBL] [Abstract][Full Text] [Related]
43. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
44. The acidosis of low-glucose pleural effusions.
Potts DE; Willcox MA; Good JT; Taryle DA; Sahn SA
Am Rev Respir Dis; 1978 Apr; 117(4):665-71. PubMed ID: 25604
[No Abstract] [Full Text] [Related]
45. Correlation between levels of tumour necrosis factor-alpha and levels of pH, glucose, and lactate dehydrogenase in parapneumonic effusions.
Odeh M; Sabo E; Srugo I; Oliven A
J Infect; 2005 Feb; 50(2):114-9. PubMed ID: 15667911
[TBL] [Abstract][Full Text] [Related]
46. Blood-pleural fluid glucose and pleural fluid pH, pCO2 relationship. A report of 80 cases of heterogeneous population with the study after intravenous glucose.
Limthongkul S; Charoenlap P; Udompanich V; Nuchprayoon C; Songkhla YN
J Med Assoc Thai; 1986 Aug; 69(8):415-21. PubMed ID: 3097229
[No Abstract] [Full Text] [Related]
47. Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders.
Werle B; Sauckel K; Nathanson CM; Bjarnadottir M; Spiess E; Ebert W; Abrahamson M
Biol Chem; 2003 Feb; 384(2):281-7. PubMed ID: 12675521
[TBL] [Abstract][Full Text] [Related]
48. [Cytologic picture of rheumatoid pleural effusion].
Roglić M; Pongrac I
Lijec Vjesn; 1987; 109(4-5):157-61. PubMed ID: 3613833
[No Abstract] [Full Text] [Related]
49. The metabolic behaviour of the cellular populations in the pleural or peritoneal effusions from patients with malignant diseases.
Mihăilescu E; Micu D; Cheţa N; Chiriloiu C; Georgescu M; Vilău C
Med Interne; 1986; 24(3):227-33. PubMed ID: 2430328
[TBL] [Abstract][Full Text] [Related]
50. Investigation of volatile organic metabolites in lung cancer pleural effusions by solid-phase microextraction and gas chromatography/mass spectrometry.
Liu H; Wang H; Li C; Wang L; Pan Z; Wang L
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():53-9. PubMed ID: 24321761
[TBL] [Abstract][Full Text] [Related]
51. [Cytological, biochemical and immunologic parameters of pleural effusions. Presentation of differences in relation to the nature of the effusion].
Kruszewski J; Płusa T; Maleszka P
Pneumonol Alergol Pol; 1991; 59(7-8):47-50. PubMed ID: 1843634
[TBL] [Abstract][Full Text] [Related]
52. [Evaluation of vascular endothelial growth factor (VEGF) in neoplastic and tuberculosis effusions--preliminary results].
Jankowska R; Porebska I; Dyła T
Pneumonol Alergol Pol; 2002; 70(5-6):258-64. PubMed ID: 12518624
[TBL] [Abstract][Full Text] [Related]
53. Radioimmunoassay determinations of prostaglandin E in pleural effusions of varying causes.
Jenkinson SG; Banschbach MW
Am Rev Respir Dis; 1982 Jul; 126(1):21-4. PubMed ID: 7091905
[TBL] [Abstract][Full Text] [Related]
54. Pleural fluid interleukin-8 and C-reactive protein for discriminating complicated non-purulent from uncomplicated parapneumonic effusions.
Porcel JM; Galindo C; Esquerda A; Trujillano J; Ruiz-González A; Falguera M; Vives M
Respirology; 2008 Jan; 13(1):58-62. PubMed ID: 18197912
[TBL] [Abstract][Full Text] [Related]
55. Comparison of telomerase activity between malignant and tuberculous pleural effusions.
Maneechotesuwan K; Lertworawiwat A; Tscheikuna J; Wamanuttajinda V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S46-54. PubMed ID: 17718245
[TBL] [Abstract][Full Text] [Related]
56. [Biochemical symptoms of pleural effusions. (Considerations and case studies)].
Zanotelli F; Zanini S; Vignola D; Galvani A
Fracastoro; 1970; 63(1):5-17. PubMed ID: 5477739
[No Abstract] [Full Text] [Related]
57. Osteopontin is upregulated in malignant and inflammatory pleural effusions.
Moschos C; Porfiridis I; Psallidas I; Kollintza A; Stathopoulos GT; Papiris SA; Roussos C; Kalomenidis I
Respirology; 2009 Jul; 14(5):716-22. PubMed ID: 19476604
[TBL] [Abstract][Full Text] [Related]
58. Acute phase markers for the differentiation of infectious and malignant pleural effusions.
Kiropoulos TS; Kostikas K; Oikonomidi S; Tsilioni I; Nikoulis D; Germenis A; Gourgoulianis KI
Respir Med; 2007 May; 101(5):910-8. PubMed ID: 17270413
[TBL] [Abstract][Full Text] [Related]
59. [Deviations in glycoprotein contents in malignant ascitic fluid and pleural effusions].
Ohtani H
Rinsho Byori; 1983 Sep; 31(9):940-4. PubMed ID: 6663770
[No Abstract] [Full Text] [Related]
60. Th1 and Th2 cytokine profiles in malignant pleural effusion.
Ghayumi MA; Mojtahedi Z; Fattahi MJ
Iran J Immunol; 2011 Dec; 8(4):195-200. PubMed ID: 22201616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
